News & Updates
Showing Multidisciplinary articles
Showing
Oral paclitaxel on par with IV formulation in HER2-negative breast cancer
A novel oral formulation of paclitaxel, DHP107, is noninferior to weekly intravenous (IV) paclitaxel in the treatment of HER2-negative recurrent or metastatic breast cancer, as shown by the results of the phase III OPTIMAL study.
Oral paclitaxel on par with IV formulation in HER2-negative breast cancer
08 Jul 2026
MonumenTAL-3 supports talquetamab–daratumumab ± pomalidomide for RRMM
In the phase III MonumenTAL-3 trial, talquetamab plus daratumumab (Tal-D), with or without pomalidomide, shows substantial efficacy in the treatment of relapsed/refractory multiple myeloma (RRMM), compared with daratumumab, pomalidomide, and dexamethasone (DPd).
MonumenTAL-3 supports talquetamab–daratumumab ± pomalidomide for RRMM
08 Jul 2026
Triple win for fixed-dose combo in T2D
A fixed-dose combination of the novel amylin receptor agonist cagrilintide and the approved GLP-1 receptor agonist semaglutide (CagriSema) yields better HbA1c control and weight loss in patients with type 2 diabetes (T2D) than either therapy alone or placebo in three phase III trials from the global REIMAGINE programme presented at ADA 2026. The benefits also extend to patients on insulin therapy.
